



Eleison Announces Successful Completion of Stage 1 of its Phase II Trial of ILC (Inhaled Lipid-complexed Cisplatin) for Pediatric Bone Cancer

St. Petersburg, FL, May 1, 2015 -- Eleison Pharmaceuticals LLC, a specialty pharmaceutical company developing life-saving therapeutics for rare cancers, has announced it has successfully completed the first stage of its Phase II study of ILC (Inhaled Lipid-complexed Cisplatin), for the treatment of patients with pediatric osteosarcoma (bone cancer), with all 19 patients enrolled in this stage of the study having reached the study endpoint. The study has been enrolling patients at 15 of the leading U.S. hospitals and medical centers. More information about the study may be found at the www.clinicaltrials.gov website.

"In this study, we were evaluating if ILC may delay or prevent further pulmonary relapses in osteosarcoma patients", commented Mr. Edwin Thomas, CEO of Eleison. "We are very encouraged by the data generated by the study as 13 of the 19 patients experienced a relapse-free interval longer than the predicted relapse-free interval", further commented Mr. Thomas. Eleison is continuing to evaluate the study data and is planning to commence a pivotal registrational clinical trial of ILC later this year.

About Pediatric Osteosarcoma

In the U.S., 500 children and young adults are diagnosed with osteosarcoma each year, a type of bone cancer. Standard therapy includes a combination of surgery and chemotherapy, although 30-35% of patients will experience a recurrence, most often in the lungs and only in the lungs. The prognosis for relapsed patients with pulmonary metastases is particularly grim, with five year survival of less than 25%.

About ILC

Eleison has an exclusive worldwide license to ILC, a novel, sustained release formulation of cisplatin in a nanoscale lipid based complex administered via inhalation. ILC was designed to deliver high levels of sustained release cisplatin targeted to the lung, without systemic-related toxicities.

About Eleison Pharmaceuticals

Eleison's mission is to acquire, develop, and commercialize clinical stage drug candidates for "orphan" oncology indications, providing new hope for patients with rare life-threatening diseases. In addition to ILC, Eleison is developing Glufosfamide, a Phase III drug candidate for the treatment of patients with pancreatic cancer, and is in discussions to acquire other promising candidates for rare cancers. Eleison was founded in 2009 and is headquartered in St. Petersburg, FL.

Forward Looking Statements

Except for statements of historical fact, the statements in this news release are forward-looking statements, including statements regarding Eleison's product candidates, their uses and potential benefits and clinical trial results and plans. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Eleison's ability to enroll and complete its current and anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, the possibility that results from these trials will not be confirmed, potential adverse side effects, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Eleison does not intend to update any forward-looking statement made in this news release.

COMPANY CONTACT: Eleison Pharmaceuticals LLC
Corporate Communications
263 13th Avenue South, Suite 375
St. Petersburg, FL 33701
tel: 215-554-3530
email: info@eleison-pharma.com